Cardiovascular, Renal and Metabolism (CVRM)

We aim to save the lives of people who suffer from cardiovascular disease, heart failure, chronic kidney disease and diabetes, by advancing CVRM solutions and addressing shared risk factors between these distinct but interrelated disease areas

Our aim is to protect the lives of 50 million people in the next year from the often-devastating consequences of heart failure, cardiovascular, metabolic and renal diseases.

Shared risk factors of CVRM diseases are still often not diagnosed or addressed, 1-4 and we are committed to help change clinical practice, to address unmet medical needs and create a seamless disease management pathway for patients worldwide.

Up to 20 million 

people die from CVRM diseases each year, making them the leading causes of death across the globe5,6

Up to 94% 

of people with type-2 diabetes in the US have at least one other cardiovascular, renal or metabolic condition7

More than 40%

of patients with heart failure also have chronic kidney disease8

Up to 40%

of patients hospitalised for heart failure have diabetes9

Our disease areas

In the spotlight

Our medicines

We cannot provide detailed information about our prescription medicines on this website, in compliance with regulations. Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. In some cases, healthcare professionals and patients can visit local AstraZeneca websites to find out more about our medicines. Please note that in some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.

Atacand, Atacand HCT, Atacand Plus

candesartan cilexetil






exenatide injection






saxagliptin and metformin HCl

Kombiglyze XR

saxagliptin and metformin XR


Sodium zirconium cyclosilicate



Plendil, Modip, Splendil, Munobal, Flodil 



dapagliflozin and saxagliptin

Seloken ZOK, Toprol-XL, Betaloc ZOK

metoprolol succinate


pramlintide acetate

Tenormin, Tenormine, Prenormine, Atenol 



dapagliflozin and metformin HCI


dapagliflozin and metformin HCI extended-release


lisinopril dihydrate

Our pipeline for CVRM

We hear our patients’ stories and see the burden that cardiovascular, renal and metabolic diseases poses on populations across the world. We work daily to discover and advance clinical practice and therapies to ultimately improve lives and address unmet needs.

Today, we believe we are the only pharmaceutical company with a full portfolio of potential CVRM solutions.

With more than 25 therapies and therapy combinations in our early-to-late stage pipeline, we seek to bring real science and development to combatting life-threatening conditions. Our first-class scientific research today is setting the stage for our pioneering approach in the fields of disease regression and organ regeneration, putting us a step closer to making science fiction a reality. 

We follow the science to develop innovative treatments and ultimately, modify or even halt the natural course of the disease and regenerate organs. We are agnostic to drug modality, we identify and validate novel targets based on genetics and human target validation and then apply the best modality to modulate the target. Together with key experts throughout the world we collaborate to accelerate our scientific progress, and to further define patient populations that may benefit from the novel cardio-renal-metabolic therapies we are developing.

Regina Fritsche-Danielson SVP, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D

New modalities

New technologies

New biology

Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III, or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets (removed when launched in all applicable major markets).


Cardiovascular, Renal and Metabolism (as of 29 April 2022)

Phase I

Phase I

  • AZD2373 nephropathy
  • AZD2693 non-alcoholic steatohepatitis
  • AZD3366 cardiovascular disease
  • AZD3427 cardiovascular disease
  • AZD5462 cardiovascular disease
  • AZD7503 non-alcoholic steatohepatitis
  • MEDI8367 chronic kidney disease

Phase II

Phase II

  • AZD4831 heart failure with a preserved ejection fraction
  • AZD5718 coronary artery disease / chronic kidney disease
  • AZD8233 hypercholesterolemia
  • AZD8601 cardiovascular disease
  • AZD9977 + Farxiga/Forxiga heart failure with CKD
  • cotadutide type-2 diabetes, obesity and NASH, diabetic kidney disease
  • MEDI6570 cardiovascular disease
  • tozorakimab diabetic kidney disease
  • zibotentan + Farxiga/Forxiga ZENITH-CKD chronic kidney disease

Phase III

Phase III

  • eplontersen patients with hereditary or wild-type transthyretin-mediated amyloid cardiomyopathy (ATTR CM)
  • eplontersen patients with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN)
  • roxadustat OLYMPUS ROCKIES anaemia in chronic kidney disease/end-stage renal disease

LCM Projects

LCM Projects

  • Andexxa (ALXN2070) Acute Major Bleed
  • Andexxa (ALXN2070) urgent surgery
  • Brilinta/Brilique THALES acute ischaemic stroke or transient ischaemic attack
  • Bydureon BCise (autoinjector) type-2 diabetes
  • Farxiga/Forxiga DAPA-CKD renal outcomes and cardiovascular mortality in patients with chronic kidney disease
  • Farxiga/Forxiga DAPA-MI Prevention of heart failure and CV death following a myocardial infarction
  • Farxiga/Forxiga DELIVER worsening HF or CV death in patients with chronic heart failure (HFpEF)
  • Lokelma DIALIZE-Outcomes CV outcomes in patients on chronic haemodialysis with hyperkalaemia
  • Lokelma STABILIZE-CKD hyperkalaemia in CKD
  • roxadustat anaemia in myelodysplastic syndrome
  • roxadustat chemotherapy induced anaemia
  • Xigduo XR/Xigduo type-2 diabetes

Our people

Strengthened by collaboration

We cannot change the future alone. Therefore, we are actively investing in broader and stronger partnerships with respected academic institutions, research organisations, patient advocacy groups, and healthcare companies. Together with our dedicated partners, we are paving the way for clinical practice evolution, tapping into this collaboration as our brick foundation.


Latest news


1.      Bjornstad et al. Curr Opin Endocrinol Diabetes Obes. 2014 August ; 21(4): 279–286. doi:10.1097/MED.0000000000000074.

2.      Narisa Futrakul, Ankanee Chanakul, Prasit Futrakul & Tawatchai Deekajorndech (2015) Early stage of vascular disease and diabetic kidney disease: an underrecognized entity, Renal Failure, 37:8, 1243-1246, DOI: 10.3109/0886022X.2015.1073054

3.      Liviu Segall, Ionut Nistor, and Adrian Covic, “Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review,” BioMed Research International, vol. 2014, Article ID 937398, 21 pages, 2014.

4.      Edelman Intelligence Relevance and barriers amongst EU specialists Survey 2018. Document ID: Z2-0050 | Date of preparation: August 2018 | Date of expiry: July 2020

5.      Wang H et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015. The Lancet 2016; 388(10053):1459–544.

6.      World Health Organization. (2019). World Heart Day. [online] Available at: [Accessed 31 Jul. 2019].

7.      Arnold SV et al. Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. Diabetes Obes Metab 2018; 20(8):2000–3.

8.      Shiba N, Shimokawa H. Chronic kidney disease and heart failure--Bidirectional close link and common therapeutic goal. J Cardiol 2011; 57(1):8–17.

9.      ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal (2013) 34, 3035–3087 doi:10.1093/eurheartj/eht108

10.   JernBerg T et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J 2015; 36:1163-1170.

11.   National Institute of Diabetes and Digestive and Kidney Diseases. Kidney Disease Statistics for the United States: December 2016. National Institutes of Health [cited 2018 Aug 28]. Available from: URL:

12.   AstraZeneca data on file. Programme screening and treatment & Total programme KPIs. June 2019.

13.   R.L. Sacco et al. The Heart of 25 by 25: Achieving the Goal of Reducing Global and Regional Premature Deaths from Cardiovascular Diseases and Stroke. Circulation 2016; 133:e674-e690. Available at: Last accessed July 2019.